• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雷诺现象患者冷激发试验的可重复性。

Reproducibility of cold provocation in patients with Raynaud's phenomenon.

作者信息

Wigley F M, Malamet R, Wise R A

机构信息

Department of Medicine, Johns Hopkins Medical Institutions, Francis Scott Key Medical Center, Baltimore, MD 21224.

出版信息

J Rheumatol. 1987 Aug;14(4):751-5.

PMID:3668980
Abstract

Twenty-five patients with Raynaud's phenomenon had serial cold challenges during a double blinded drug trial. The data were analyzed to determine the reproducibility of cold provocation in the induction of critical closure of the digital artery in patients with Raynaud's phenomenon. Finger systolic pressure (FSP) was measured after local digital cooling using a digital strain gauge placed around the distal phalanx. Nineteen of 25 patients completed the study. The prevalence of inducing a Raynaud's attack decreased with each successive cold challenge from 74% of patients at initial challenge to 42% at the 3rd challenge. A lower temperature was required to induce a Raynaud's attack at last challenge (10.6 +/- 0.6 degrees C) compared to the first cold challenge (13.2 +/- 1.0 degrees C). Our data demonstrate adaptation to a laboratory cold challenge through the winter months in patients with Raynaud's phenomenon and show it is an important factor in objectively assessing drug efficacy in the treatment of Raynaud's phenomenon.

摘要

在一项双盲药物试验中,25名患有雷诺现象的患者接受了一系列冷刺激试验。对数据进行分析,以确定在患有雷诺现象的患者中,冷激发试验诱导指动脉临界闭合的可重复性。使用置于远端指骨周围的数字应变仪在局部手指冷却后测量手指收缩压(FSP)。25名患者中有19名完成了研究。诱发雷诺发作的发生率在每次连续冷刺激试验中逐渐降低,从初次刺激时74%的患者降至第三次刺激时的42%。与第一次冷刺激试验(13.2±1.0℃)相比,最后一次刺激试验(10.6±0.6℃)诱发雷诺发作所需的温度更低。我们的数据表明,患有雷诺现象的患者在冬季几个月中对实验室冷刺激试验产生了适应性,并且表明这是客观评估治疗雷诺现象药物疗效的一个重要因素。

相似文献

1
Reproducibility of cold provocation in patients with Raynaud's phenomenon.雷诺现象患者冷激发试验的可重复性。
J Rheumatol. 1987 Aug;14(4):751-5.
2
Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.雷诺病局部冷却时的数字压力和流量测量。萘呋胺酯的作用。
Int Angiol. 1986 Jan-Mar;5(1):39-44.
3
Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.对冷敏感、原发性雷诺现象或硬皮病谱系障碍患者进行降温时的数字血管反应。
J Rheumatol. 1996 Dec;23(12):2068-78.
4
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.静脉注射伊洛前列素治疗系统性硬化症继发的雷诺现象和缺血性溃疡。
J Rheumatol. 1992 Sep;19(9):1407-14.
5
[Hemodynamic response of the digital artery to heat and cold in normal subjects, in systemic scleroderma and in Raynaud's disease].[正常受试者、系统性硬化症患者及雷诺病患者指动脉对热和冷的血流动力学反应]
J Mal Vasc. 1984;9(1):7-10.
6
Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.尼卡地平治疗雷诺现象:一种新型钙通道阻滞剂的双盲交叉试验
J Rheumatol. 1987 Aug;14(4):745-50.
7
Treatment of Raynaud's phenomenon with captopril.卡托普利治疗雷诺现象
Drugs Exp Clin Res. 1987;13(1):37-42.
8
Use of biofeedback training in treatment of Raynaud's disease and phenomenon.生物反馈训练在雷诺病及雷诺现象治疗中的应用。
J Rheumatol. 1985 Feb;12(1):90-3.
9
[Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].硝苯地平对雷诺现象缺血后冷充血反应的作用
J Mal Vasc. 1989;14(4):299-302.
10
Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.激光多普勒皮肤灌注压在雷诺现象评估中的应用
Eur J Vasc Endovasc Surg. 2004 Apr;27(4):414-6. doi: 10.1016/j.ejvs.2003.12.017.

引用本文的文献

1
Vasodilators for primary Raynaud's phenomenon.用于原发性雷诺现象的血管扩张剂。
Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4.
2
Calcium channel blockers for primary Raynaud's phenomenon.用于原发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5.
3
Oral vasodilators for primary Raynaud's phenomenon.用于原发性雷诺现象的口服血管扩张剂。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD006687. doi: 10.1002/14651858.CD006687.pub3.
4
Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.量化原发性雷诺现象和系统性硬化症患者的数字血管疾病。
Ann Rheum Dis. 1998 Feb;57(2):70-8. doi: 10.1136/ard.57.2.70.